VBS Voted By Industry Peers Best Biotech Drug Pipeline of 2015

VBS announced the award of a $1.2 million, milestone-based, 3-year contract from the National Heart Lung Blood Institute (NHLBI) of the National Institutes of Health (NIH) to expedite the development of CAR therapeutic peptide pulmonary hypertension

Vascular BioSciences announces the publication of "Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension" to the current issue of the Pulmonary Circulation.

CEO David Mann will present "CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy" during the 7th Annual Therapeutic Peptide Symposium hosted at The Salk Institute in La Jolla, CA on October 25th and 26th.

A recently published paper from Vascular Biosciences (VBS) has been selected by the Faculty of 1000 (F1000) as one of the top 2 percent of all published articles in the biological and medical sciences in 2011.